Single-Dose Tafenoquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria

Abstract

Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167 .).